tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk Effects of tirzepatide on adjudicated

Oral Tirzepatide questions Things people ask before they sign up

Finerenone is recommended as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. Kerendia can cause some mild side effects: Low blood pressure

The peptide economy is booming

The Dual Agonist Breakthrough: Why Two Is Better Than One Tirzepatide, the first dual GLP-1/GIP agonist to reach market, demonstrated that activating both receptors produces superior results to activating GLP-1 alone

So if you are on your first injection and wondering why the scale has not moved, that is expected

After this initial month, it is recommended to increase the dose to 7 mg of Rybelsus once daily3